FY2025 · ended Dec 31, 2025 · Revenue $1.07B, +11.9% YoY · Filed Feb 26, 2026
Acadia Pharmaceuticals Inc. (ACAD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.1 billion and net income of $391.0 million. Free cash flow was $105.1 million. As of Jun 30, 2026 it held $956.5 million in cash and investments and $73.9 million in total debt.
Revenue (TTM)
$1.14B
+11.8% vs year-ago TTM
Net income (TTM)
$380.48M
+71.3% vs year-ago TTM
Operating cash flow (TTM)
$160.32M
-14.7% vs year-ago TTM
Free cash flow (TTM)
$145.62M
EPS (TTM)
$2.21
+148.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
170.49M
+2.2% vs prior year
Net cash
$882.62M
as of Jun 30, 2026
Operating margin
7.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACAD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1070494
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $957.8M | $726.4M | $517.2M | $484.1M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M | -$170.4M |
| Net income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M |
| Diluted EPS | $2.30 | $1.36 | -$0.37 | -$1.34 | — |
| Operating cash flow | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M |
| Total assets | $1.6B | $1.2B | $749.0M | $587.8M | $700.1M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M |
| Stockholders' equity | $1.2B | $732.8M | $431.8M | $400.4M | $540.9M |
| Cash and investments | $819.7M | $756.0M | $438.9M | $416.8M | $520.7M |
| Total debt | $52.2M | $52.0M | $57.2M | $62.0M | $64.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 11, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 1002 Acadia Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.